en English
af Afrikaanssq Shqipam አማርኛar العربيةhy Հայերենaz Azərbaycan dilieu Euskarabe Беларуская моваbn বাংলাbs Bosanskibg Българскиca Catalàceb Cebuanony Chichewazh-CN 简体中文zh-TW 繁體中文co Corsuhr Hrvatskics Čeština‎da Dansknl Nederlandsen Englisheo Esperantoet Eestitl Filipinofi Suomifr Françaisfy Fryskgl Galegoka ქართულიde Deutschel Ελληνικάgu ગુજરાતીht Kreyol ayisyenha Harshen Hausahaw Ōlelo Hawaiʻiiw עִבְרִיתhi हिन्दीhmn Hmonghu Magyaris Íslenskaig Igboid Bahasa Indonesiaga Gaeligeit Italianoja 日本語jw Basa Jawakn ಕನ್ನಡkk Қазақ тіліkm ភាសាខ្មែរko 한국어ku كوردی‎ky Кыргызчаlo ພາສາລາວla Latinlv Latviešu valodalt Lietuvių kalbalb Lëtzebuergeschmk Македонски јазикmg Malagasyms Bahasa Melayuml മലയാളംmt Maltesemi Te Reo Māorimr मराठीmn Монголmy ဗမာစာne नेपालीno Norsk bokmålps پښتوfa فارسیpl Polskipt Portuguêspa ਪੰਜਾਬੀro Românăru Русскийsm Samoangd Gàidhligsr Српски језикst Sesothosn Shonasd سنڌيsi සිංහලsk Slovenčinasl Slovenščinaso Afsoomaalies Españolsu Basa Sundasw Kiswahilisv Svenskatg Тоҷикӣta தமிழ்te తెలుగుth ไทยtr Türkçeuk Українськаur اردوuz O‘zbekchavi Tiếng Việtcy Cymraegxh isiXhosayi יידישyo Yorùbázu Zulu

Cancer Research Month: SBRT Shows Effectiveness for Early-Stage Lung Cancer

The American Association for Cancer Research acknowledges May as National Cancer Research Month to recognize high-quality, innovative cancer research and make it a top priority. Through various studies, researchers are able to identify cancer risk factors and evaluate optimal treatment options for cancer patients.

One recent study revealed excellent long-term, local control rates for medically inoperable, early stage lung cancer patients treated with stereotactic body radiation therapy (SBRT). From 2003 to 2012, 300 patients with a total of 340 lesions were treated with SBRT.

According to the 10 years of data collected, the results revealed excellent, sustained local control with minimal side effects for medically inoperable, early stage lung cancer patients who received high-dose rate stereotactic body radiotherapy (SBRT).

The results provide significant evidence and support for SBRT as a viable treatment option for early-stage lung cancer.

To learn more about this study and read the full results, click here.

Austin CyberKnife treats primary, recurrent and metastatic lung tumors with SBRT using CyberKnife® technology. To learn more about our treatment process, click here.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.